Verve Therapeutics, Inc.

NasdaqGS:VERV Stock Report

Market Cap: US$410.6m

Verve Therapeutics Valuation

Is VERV undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of VERV when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate VERV's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for VERV?

Key metric: As VERV is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for VERV. This is calculated by dividing VERV's market cap by their current revenue.
What is VERV's PS Ratio?
PS Ratio16.8x
SalesUS$24.40m
Market CapUS$410.62m

Price to Sales Ratio vs Peers

How does VERV's PS Ratio compare to its peers?

The above table shows the PS ratio for VERV vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average32.6x
ACIU AC Immune
7.3x32.0%US$334.4m
LXRX Lexicon Pharmaceuticals
59.7x59.5%US$312.1m
TRDA Entrada Therapeutics
3.1x-77.2%US$665.6m
IMNM Immunome
60.5x65.0%US$612.9m
VERV Verve Therapeutics
16.8x-20.4%US$410.6m

Price-To-Sales vs Peers: VERV is good value based on its Price-To-Sales Ratio (16.8x) compared to the peer average (32.6x).


Price to Sales Ratio vs Industry

How does VERV's PS Ratio compare vs other companies in the US Biotechs Industry?

129 CompaniesPrice / SalesEstimated GrowthMarket Cap
GILD Gilead Sciences
4x2.4%US$112.40b
BIIB Biogen
2.4x1.3%US$23.01b
MRNA Moderna
3.1x6.8%US$15.82b
INCY Incyte
3.4x8.9%US$13.82b
VERV 16.8xIndustry Avg. 9.6xNo. of Companies129PS01632486480+
129 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: VERV is expensive based on its Price-To-Sales Ratio (16.8x) compared to the US Biotechs industry average (9.6x).


Price to Sales Ratio vs Fair Ratio

What is VERV's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

VERV PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio16.8x
Fair PS Ratio0.007x

Price-To-Sales vs Fair Ratio: VERV is expensive based on its Price-To-Sales Ratio (16.8x) compared to the estimated Fair Price-To-Sales Ratio (0x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst VERV forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$4.85
US$26.20
+440.3%
31.4%US$40.00US$14.00n/a9
Nov ’25US$5.93
US$26.01
+338.6%
28.2%US$40.00US$15.00n/a10
Oct ’25US$4.79
US$26.01
+443.0%
28.2%US$40.00US$15.00n/a10
Sep ’25US$6.70
US$26.01
+288.2%
28.2%US$40.00US$15.00n/a10
Aug ’25US$6.73
US$25.78
+283.0%
27.2%US$40.00US$15.00n/a9
Jul ’25US$4.98
US$26.89
+439.9%
28.2%US$40.00US$15.00n/a9
Jun ’25US$5.19
US$26.89
+418.1%
28.2%US$40.00US$15.00n/a9
May ’25US$6.00
US$31.22
+420.4%
35.1%US$55.00US$15.00n/a9
Apr ’25US$12.79
US$48.25
+277.2%
33.0%US$75.00US$24.00n/a8
Mar ’25US$16.29
US$48.25
+196.2%
33.0%US$75.00US$24.00n/a8
Feb ’25US$11.21
US$45.89
+309.4%
36.0%US$75.00US$22.00n/a9
Jan ’25US$13.94
US$45.89
+229.2%
36.0%US$75.00US$22.00n/a9
Dec ’24US$11.79
US$46.44
+293.9%
34.3%US$75.00US$22.00n/a9
Nov ’24US$11.75
US$46.11
+292.4%
35.3%US$75.00US$22.00US$5.939
Oct ’24US$13.26
US$46.11
+247.7%
35.3%US$75.00US$22.00US$4.799
Sep ’24US$13.45
US$41.73
+210.2%
42.7%US$75.00US$13.00US$6.7011
Aug ’24US$19.42
US$42.00
+116.3%
42.4%US$75.00US$13.00US$6.7311
Jul ’24US$18.75
US$42.00
+124.0%
42.4%US$75.00US$13.00US$4.9811
Jun ’24US$15.41
US$41.82
+171.4%
43.1%US$75.00US$13.00US$5.1911
May ’24US$16.04
US$42.27
+163.5%
41.7%US$75.00US$14.00US$6.0011
Apr ’24US$14.42
US$42.60
+195.4%
41.3%US$75.00US$14.00US$12.7910
Mar ’24US$18.19
US$42.40
+133.1%
41.4%US$75.00US$13.00US$16.2910
Feb ’24US$22.07
US$42.40
+92.1%
41.4%US$75.00US$13.00US$11.2110
Jan ’24US$19.35
US$44.78
+131.4%
37.7%US$75.00US$13.00US$13.949
Dec ’23US$22.57
US$49.50
+119.3%
28.1%US$75.00US$35.00US$11.798
Nov ’23US$36.44
US$53.13
+45.8%
21.3%US$75.00US$36.00US$11.758

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies